ArticleBritish journal of cancer2016
Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.
Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection-A Systematic Review.Viruses · 2021Pooled it
- Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial.JAMA otolaryngology-- head & neck surgery · 2022Trial
- Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial.International journal of cancer · 2020Trial
- Natural Versus Vaccine-Induced Immunity Against HPV: A Comparative Review of Antibody Response and Cancer Prevention.Antibodies (Basel, Switzerland) · 2026Review
- In Silico Design and Subsequent Expression of Human Papillomavirus-16 and -18 L1 Vaccine Antigens in Broccoli.Vaccines · 2026Article
- Immune Responses to Human Papillomavirus After Infection and Vaccination.Current topics in microbiology and immunology · 2026Review
- Prevalence of serum and salivary virus-neutralizing antibodies against equine coronavirus in four riding stables in Japan.Journal of equine science · 2023Article
- [Recurrent laryngeal papillomatosis].HNO · 2023Review
- Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer.Head & neck · 2023Article
- Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway.Virology journal · 2022Article
- Human Papillomavirus-Associated Head and Neck Cancers. Where are We Now? A Systematic Review.Cancer management and research · 2022Review
- Humoral immune mechanisms involved in protective and pathological immunity during COVID-19.Human immunology · 2021Review
- Focal Epithelial Hyperplasia.Viruses · 2021Article
- Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection.Infectious agents and cancer · 2021Review
- Assessment of Two Novel Live-Attenuated Vaccine Candidates for Herpes Simplex Virus 2 (HSV-2) in Guinea Pigs.Vaccines · 2021Article
- Value and Unmet Needs in Non-Invasive Human Papillomavirus (HPV) Testing for Oropharyngeal Cancer.Cancers · 2021Review
- Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine.Frontiers in immunology · 2020Article
- Review
- Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.Antiviral research · 2019Article
- Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies.Current treatment options in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal human papillomaviruses (HPV) are a major cause of cancers and papillomas of the anogenital and oropharyngeal tract. HPV-vaccination elicits neutralising antibodies in sera and cervicovaginal secretions and protects uninfected individuals from persistent anogenital infection and associated diseases caused by the vaccine-targeted HPV types. Whether immunisation can prevent oropharyngeal infection and diseases and whether neutralising antibodies represent the correlate of protection, is still unclear.
methodsWe determined IgG and neutralising antibodies against low-risk HPV6 and high-risk HPV16/18 in sera and oral fluids from healthy females (n=20) before and after quadrivalent HPV-vaccination and compared the results with non-vaccinated controls.
resultsHPV-vaccination induced type-specific antibodies in sera and oral fluids of the vaccinees. Importantly, the antibodies in oral fluids were capable of neutralising HPV pseudovirions in vitro, indicating protection from infection. The increased neutralising antibody levels against HPV16/18 in sera and oral fluids post-vaccination correlated significantly within an individual.
conclusionsWe provide experimental proof that HPV-vaccination elicits neutralising antibodies to the vaccine-targeted types in oral fluids. Hence, immunisation may confer direct protection against type-specific HPV infection and associated diseases of the oropharyngeal tract. Measurement of antibodies in oral fluids represents a suitable tool to assess vaccine-induced protection within the mucosal milieu of the orophayrynx.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.